FREMONT, Calif., March 8 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) today announced that Andrew Guggenhime, chief financial officer, will participate in the upcoming Cowen and Company 27th Annual Healthcare Conference in Boston, Mass. on Thursday, March 15, 2007, at 8:45 a.m. Eastern time.
The live webcast of the conference call will be available through the PDL website: www.pdl.com. Please connect to this website at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. A replay will be available at www.pdl.com starting approximately one hour after completion of the webcast.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life- threatening illnesses. Commercially focused in the acute-care hospital setting, PDL markets and sells its portfolio of leading products in the United States and Canada. A pioneer of antibody humanization technology, PDL promotes this technology through licensing agreements and clinical development of its own diverse pipeline of investigational compounds. PDL’s research platform centers on the discovery and development of antibodies to treat cancer and autoimmune diseases. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL logo are considered trademarks of PDL BioPharma, Inc.
PDL BioPharma, Inc.
CONTACT: Ami Knoefler, Corporate and Investor Relations, +1-510-284-8851,or ami.knoefler@pdl.com, or Jean Suzuki, Corporate Relations,+1-510-574-1550, or jean.suzuki@pdl.com, both of PDL BioPharma, Inc.
Web site: http://www.pdl.com//
